• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4 –5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study
AbstractThe role of direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) and stage 4 –5 chronic kidney disease (CKD) is controversial. Electronic medical records from 2012 to 2021 were retrieved for patients with AF and stage 4–5 CKD receiving oral anticoagulants. Patients were separated into those receiving DOACs (dabigatran, rivaroxaban, apixaban, or edoxaban) or vitamin K ant agonists (VKA). Primary outcomes included ischemic stroke (IS), systemic thrombosis (SE), major bleeding, gastrointestinal bleeding, hemorrhagic stroke, acute myocardial infarction, cardiovascular death, and all-cause dea...
Source: Journal of Thrombosis and Thrombolysis - August 21, 2023 Category: Hematology Source Type: research

Comparison between Automated Erythrocytopharesis (AECP) and Manual Exchange Transfusion (M-Ex)) in Reducing Hb-S and in Recovery of Acute Chest Syndrome and Other Acute Presentations of Sickle Cell Disease Patients
Conclusions:Erythrocytopharesis (Automated RBC exchange) is effective, quick and safe procedure that is life saving for many patients with ACS and is associated with less difficulties and complications if compared with the manual exchange. Because SCA is a national problem in Saudi Arabia and acute chest syndrome and other acute major complications comprehensively kill SCD patients, Automated Erythocytopharesis should be available nation-wide like dialysis machines at all large hospitals in all cities and should be distributed according to the prevalence of SCA in the area or location.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - November 21, 2018 Category: Hematology Authors: Ahmed, S. Y., Saleh, S. M., Hameed, M. S., Ragheb, A. M., Abbas, T. M., Fadel, A., Hassan, S., Baden, H. S., Tayeb, K. I., Bakshi, N., El Yamany, G., Alotaibi, S. B. Tags: 114. Hemoglobinopathies, Excluding Thalassemia-Clinical Source Type: research

Cardiovascular mortality due to pulmonary embolism in subjects with renal impairment: patients’ comorbidities are crucial
Abstract we read with great interest the paper by Ocak et al. (1). The authors found that the age‐ and sex‐standardized mortality rate (SMR) for pulmonary embolism (PE) was 12.2 (95% CI 10.2‐14.6) times higher in dialysis patients than in the general population. Such SMR was even higher than that of myocardial infarction (MI) (11.0, 95% CI 10.6‐11.4), stroke (8.4 (95% CI 8.0‐8.8), and other cardiovascular disease (8.3, 95% CI 8.0‐8.5) On the one hand, the association between the different grade of impaired renal function and MI received important confirmation (2), and also a recent study from our group conducte...
Source: Journal of Thrombosis and Haemostasis - April 4, 2013 Category: Hematology Authors: Fabio Fabbian, Francesco Dentali, Walter Ageno, Roberto Manfredini Tags: Letter Rebuttal Source Type: research

Seek and You Shall Find—But Then What Do You Do? Cold Agglutinins in Cardiopulmonary Bypass and a Single-Center Experience With Cold Agglutinin Screening Before Cardiac Surgery
Abstract: Cardiopulmonary bypass (CPB) during cardiac surgery can involve deliberate hypothermia of the systemic (22-36°C) and coronary circulations (as low as 8-12°C). Adverse sequelae of cold-active antibodies have been feared and reported under such conditions, and some centers thus elect to screen for cold agglutinins before CPB. We reviewed the literature on cold agglutinins in cardiac surgery and described the yields and effects of cold agglutinin screening (CAS) in 14900 cardiac surgery patients undergoing CPB over 8 years at a single institution. Cold agglutinin screening was positive in 47 cases (0.3%), at an an...
Source: Transfusion Medicine Reviews - February 4, 2013 Category: Hematology Authors: Michael D. Jain, Rosa Cabrerizo-Sanchez, Keyvan Karkouti, Terrence Yau, Jacob M. Pendergrast, Christine M. Cserti-Gazdewich Tags: Original Articles Source Type: research

Erythropoiesis-stimulating agents and thrombotic events in dialysis patients
Erythropoiesis-stimulating agents (ESA) have been associated with a higher cardiovascular event and mortality rate in dialysis patients. The ESA-associated risk of arterial thrombotic events is mainly based on composite endpoints of anemia-correction trials targeting high hemoglobin levels. The ESA-associated risk of venous thromboembolism (VTE) has not been studied in dialysis patients yet. We therefore aimed to determine the association between ESA use and dose with ischemic stroke, myocardial infarction (MI) and VTE.
Source: Thrombosis Research - August 1, 2014 Category: Hematology Authors: Marit M. Suttorp, Tiny Hoekstra, Gürbey Ocak, Anouk T.N. van Diepen, Ilka Ott, Moshe Mittelman, Ton J. Rabelink, Raymond T. Krediet, Friedo W. Dekker Source Type: research

Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
In conclusion, based on these single-dose PK data, a supplementary dose of edoxaban may not be required following a haemodialysis session. Importantly, haemodialysis is not an effective mechanism for removal of edoxaban from the blood. PMID: 25566930 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 8, 2015 Category: Hematology Authors: Parasrampuria DA, Marbury T, Matsushima N, Chen S, Wickremasingha PK, He L, Dishy V, Brown KS Tags: Thromb Haemost Source Type: research

Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.
This study simulated the dose-exposure relationship of dabigatran in patients undergoing haemodialysis. Dabigatran exposure was modelled at once- and twice-daily doses of 75 mg, 110 mg and 150 mg and at variations in non-renal clearance and dialysis settings. Resultant dose exposure (area under the curve [AUC]) was compared with values simulated from typical patients in the RE-LY® trial (based on a previously characterised pharmacometric model). In this simulation, all twice-daily dosages resulted in exposures above those simulated from typical RE-LY patients (1.5- to 3.3-fold increase in AUC) and thus may not be optimal ...
Source: Thrombosis and Haemostasis - October 15, 2015 Category: Hematology Authors: Liesenfeld KH, Clemens A, Kreuzer J, Brueckmann M, Schulze F Tags: Thromb Haemost Source Type: research

Mortality due to bleeding, myocardial infarction and stroke in dialysis patients
Journal of Thrombosis and Haemostasis,Volume 0, Issue ja, -Not available-.
Source: Journal of Thrombosis and Haemostasis - July 31, 2018 Category: Hematology Authors: Gurbey Ocak , Marlies Noordzij , Maarten B. Rookmaaker , Aleix Cases , C écile Couchoud , James G. Heaf , Faiçal Jarraya , Johan De Meester , Jaap W. Groothoff , Bård E. Waldum‐Grevbo , Runolfur Palsson , Halima Resic , Césa Source Type: research

Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance   & lt;  30 mL/min
AbstractThe few studies that compared direct oral anticoagulants (DOAC) vs. warfarin in the setting of advanced renal insufficiency have focused on patients with atrial fibrillation. The purpose of this observational, matched, cohort study of patients was to assess the effectiveness and safety of DOAC vs. warfarin for the treatment of venous thromboembolism (VTE) among patients with a creatinine clearance (CrCl)  <  30 mL/min. This observational, cohort study included patients with VTE and CrCl <  30 mL/min who were newly initiated on a DOAC or warfarin between January 1, 2016 and December 31, 2020. DOAC pati...
Source: Journal of Thrombosis and Thrombolysis - December 23, 2022 Category: Hematology Source Type: research